# DSIP: The Delta Sleep-Inducing Peptide, Measured Study by Study

> DSIP enhanced delta and spindle EEG activity in the 1977 study that named it. A data-forward digest of the delta sleep-inducing peptide — every quantitative finding cited, every gap stated.

A data-forward digest of the delta sleep-inducing peptide — the numbers the EEG, sleep-architecture, and neuroendocrine studies actually recorded, and the places the evidence stays thin.

## The short version

DSIP stands for delta sleep-inducing peptide. It is a tiny natural molecule — a chain of nine amino acids — first pulled from the blood of sleeping rabbits in 1977 and named because, when researchers infused it into the brain, the slow "delta" brain waves of deep sleep got stronger [1]. People in research-use communities try it hoping for deeper, more restful sleep. Here is the honest part: scientists still have not found the receptor it acts on, the gene that makes it, or even a clear, repeatable mechanism. A 2006 review flatly called the sleep evidence "extremely poorly documented and still weak" [3]. Some people who try it report falling asleep more easily; a large share report feeling nothing at all. This site sums up what the studies measured — the real numbers and the real gaps. What people report, including the downsides, is on [the effects page](/effects).

## What the DSIP literature actually measured

Start with the founding number. In 1977, Schoenenberger and Monnier isolated a nonapeptide (a nine-amino-acid chain, sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) from the cerebral venous blood of rabbits in electrically induced sleep, and showed that infusing it produced a significant, specific enhancement of delta and spindle EEG activity [1]. That single result — slow brain waves, amplified — is why the molecule carries "delta sleep-inducing" in its name.

The animal EEG numbers reinforce it. In rats, DSIP produced roughly a 35% mean increase in neocortical and limbic delta EEG power, with more frequent theta bursts and changes sustained for up to 11 hours [9]. In cats, 120 nmol/kg given under the skin significantly increased slow-wave sleep without suppressing REM and reduced waking — evidence that peripherally injected DSIP can still reach the central nervous system [10].

The human numbers are smaller and older. In six middle-aged chronic insomniacs, a single intravenous dose of 25 nmol/kg lengthened sleep, cut interruptions, slightly raised REM, and produced no daytime sedation — with the sleep-promoting effect appearing in the second hour after injection, not the first [2]. A later report in severe chronic insomnia described improved sleep efficiency and duration plus significant daytime alertness gains, carrying into the first post-treatment night [7].

## DSIP

Beyond sleep, DSIP shows up across the neuroendocrine literature — which is part of why its story is hard to pin down. Intravenous DSIP at 25 nmol/kg in men cut plasma ACTH-like immunoreactivity for at least three hours while leaving cortisol on its normal daily decline [4], pointing at the hypothalamic-pituitary-adrenal (HPA) axis (the body's stress-hormone system). The molecule has also been detected endogenously — in plasma, cerebrospinal fluid, and even milk, usually bound to a carrier protein, and in gut endocrine cells, with the human gut its richest known source [13]. A phosphorylated natural form, DSIP-P, is reported as more potent than the parent peptide in some assays [11]. The catch running through all of it: no DSIP gene, precursor protein, or specific receptor has ever been conclusively identified [3].

## What stays unproven

The honest gaps matter as much as the findings. The signature sleep effect has been inconsistently replicated, and a 2006 Journal of Neurochemistry review concluded that synthetic analogs — not native DSIP — often drove the clearest effects, calling the whole picture a "still unresolved riddle" [3]. Cross-species results diverge: rat data show DSIP raising growth hormone through a dopamine pathway, but the human and longevity claims rest on smaller or single-lineage datasets [11][3]. There is no large randomized controlled trial, no validated human pharmacokinetic profile, and no regulatory approval for any use [3]. DSIP is not approved by the FDA or any other regulator; "Emideltide" is its international nonproprietary name, but no Emideltide product has ever been marketed. The full [DSIP research](/research) record — including the 2024 fusion-peptide work — is laid out study by study, and [DSIP for sleep](/for-sleep) collects the sleep-architecture numbers in one place.

---

A data-forward digest of the delta sleep-inducing peptide literature — every figure sourced, every gap named, and no clinic, vendor, or prescription behind the numbers.